Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-02
2000-08-08
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514507, 514256, 514277, 514365, 514473, 514218, 514 49, A01N 4342, A01N 3728, A01N 4354, A01N 4340
Patent
active
061002771
ABSTRACT:
The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo. This invention, in particular, relates to protease inhibitor compounds used in combination therapy with other protease inhibitor compounds. This invention also relates to combination therapy with a combination of protease inhibitors and antiviral agents other than protease inhibitors.
REFERENCES:
patent: H1649 (1997-05-01), Barrish et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4857511 (1989-08-01), Rideout et al.
patent: 5122517 (1992-06-01), Vince et al.
patent: 5157041 (1992-10-01), Handa et al.
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5458889 (1995-10-01), Bourbon et al.
patent: 5476874 (1995-12-01), Hungate et al.
patent: 5484926 (1996-01-01), Dressman et al.
patent: 5504104 (1996-04-01), Elsworth et al.
patent: 5527799 (1996-06-01), Vacca et al.
patent: 5585397 (1996-12-01), Tung et al.
Merry, et al., "Saquinavir Pharmacokinetics Alone and in Combination With Ritonavir in HIV-Infected Patients," F29-F33, 1997.
Richman, et al., "Protease Uninhibited," Nature, vol. 374, 1995.
Barry, et al., "Protease Inhibitors in Patients with HIV Disease Clinically Important Pharmacokinetic Consideration," Pharmaceokinetic-Pharmacodynamic Relationships, pp. 194-209, 1997.
Abstract No. 245, "Efficacy and safety of Quadruple Combination Therapy in Treatment Experienced HIV/AIDS Patient," 4th Conf Retro and Opportun Infect, Jan. 22-26, 1997, p. 103.
Abstract No. 209, "Selection and Analysis of HIV-1 Variants With Increased Resistance to ABT-378, A Novel Protease Inhibitor," 4th Conf Retro and Opportun Infect, Jan. 22-26, 1997, p. 103.
Abstract No. 199, "`Salvage Therapy`Using the Combination of Ritonavir and Saquinavir in Patients with Advanced HIV Infection," 4th Conf Retro and Opportun Infect, Jan. 22-26, 1997, p. 101.
Abstract No. 257, "The Use of Antiretroviral Therapy in Association With Evolving Standards of Practice," 4th Conf Retro and Opportun Infect, Jan. 22-26, 1997, p. 111.
Abstract No. 609, "Pharmacokinetics/pharmacodynamics of Ritonavir-Saquinavir Combination Therapy," 4th Conf Retro and Opportun Infect, Jan. 22-26, 1997, p. 177.
Abstract No. Th.B. 934, "Combination Use of Ritonavir and Saquinavir in HIV-Infected Patients: Preliminary Safety and Activity Data," Int Conf Aids (United States), Jul. 7-12, 1996 (Program Supplement, p. 20).
Abstract, "Saquinavir Pharmacokinetics Alone and in Combination With Ritonavir in HIV-Infected Patients," United Kingdom, AIDS (1997) Nov. 4.
Abstract, "Ritonavir," Bioorganic and Medicinal Chemistry, (1997) 5/3 (461-462).
Abstract. "Protease Inhibitors in Patients With HIV Disease. Clinically Important Pharmacokinetic Considerations," Clinical Pharmacokinetics, (1977) 32/3 (194-209).
El-Farrash et al., "Generation and Characterization of a Human Immunodeficiency Virus Type 1 (HIV-1) Mutant Resistant to an HIV-1 Protease Inhibitor", Journal of Virology, Jan. 1994, pp. 233-239.
Lang, M., Archiv der Pharmazie, vol. 326(9) (1993) p. 574.
Fischl, "Combination Antiretroviral Therapy for HIV Infection" Hospital Practice, Jan. 15, 1994, pp. 43-48.
Larder et al., "Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy", Science 269:696-699 (1995).
Patick et al., "Characterization of a Human Immunodeficiency Virus Type 1 Variant with Reduced Sensitivity to an Aminodiol Protease Inhibitor", J. Virology 69(4):2148-2152 (1995).
Hirsch et al., "Therapy for Human Immunodeficiency Virus Infection", New England J. Med., 328(23):1686-1695 (1993).
Getman et al., "Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere", J. Med. Chem. 36:288-291 (1993).
Tam et al., "Intriguing Structure-Activity Relations Underlie the Potent Inhibition of HIV Protease by Norstatine-Based Peptides", J. Med. Chem. 35:1318-1320 (1992).
Clare et al., "Preparation of N-(3-hydroxy-1-phenyl-4-urei=do-2-butyl)asparaginamidesand Analogs as Retroviral Protease Inhibitors", Chem. Abst. 738:117:251771f (1992).
Doerr et al., "Neue Entwicklungen in der Antiviralen Chemotherapie", PZ Prisma 1:36-45 (1994).
Merck Index, 10th Ed., 1984, #3092.
Condra et al., "In vivo Emergence of HIV-1 Variants Resistant to Multiple Protease Inhibitors", Nature 374:569-571 (1995).
Roberts et al, Science, 248, 358-361, (1990).
Erickson et al, Science, 249, (1990).
Waldholz, The Wall Street Journal, p. B3, Feb. 25, 1994.
Vacca et al, Proc. Natl. Acad. Sci. USA, 91:4096-4100 (1994).
Ho et al, J. Virol., 68:2016-2020 (1994).
Sardana et al, Biochem., 33:2004-2010 (1994).
Loeb et al, Nature, 340:397-400 (1989).
Tet. Lett., 35:673-676 (1994).
Drugs of the Future, 16(3), 210-212 (1991).
Kagayama et al, Antimicrobial Agents and Chemotherapy 1993, 810-817.
Lam et al, "De Novo Design and Discovery of Potent, Nonpeptidal HIV-1 Protease Inhibitors", paper 96 at the 205th American Chemical Society National Meeting, Medicinal Chemistry Division, Denver, CO, Mar. 28-Apr. 2, 1993.
Dorsey et al, "L-735, 524: The Rational Design of a Potent and Orally Bioavailable HIV Protease Inhibitor", paper 6 at the 206th American Chemical Society National Meeting, Medicinal Chemistry Division, Chicago, IL, Aug. 22-27, 1993.
Wei et al, J. Med. Chem., 36, 249-255 (1993).
Hoffman et al, J. Med. Chem., 35, 3784-3791 (1992).
Saari et al, J. Med. Chem., 35, 3792-3802 (1992).
Romero et al, J. Med. Chem., 36, 1505-1508 (1993).
Hargrave, J. Med. Chem., 34, 2231-2241 (1991).
Merluzzi, Science, 250, 1411-1413 (1990).
Williams et al, J. Med. Chem., 36, 1291-1294 (1993).
Hsu et al, Proc. Natl. Acad. Sci. USA, 909, 6395-6399 (1993).
S.J. Fittkau, J. Prakt. Chem., 315, 1037 (1973).
Parikh et al., J. Am. Chem. Soc., 89, 5505 (1967).
Reetz et al, Angew Chem. Int. Ed. Engl., 26, 1141 (1987).
Miller et al, Science, 246, 1149 (1989).
Meek et al, Nature, 343, (1990).
T.J. McQuade et al, Science, 247, 454-456 (1989).
Rich et al, Peptide Inhibitors of Proteases, 511-520, 1987.
Pearle, et al, Nature, 328, 482 (1987).
Fletcher, Pharmacotherapy, 13(6), 627-33 (1993).
Perno et al, J. Infect. Disease, 168:1148-1156 (1993).
Yarcham et al, J. Infect. Disease, 169:9-17 (1994).
Bryant Martin L
Potts Karen E
Smidt Mary L
Tucker Simon P
Cintins Marianne M.
G.D. Searle & Co.
LandOfFree
Retroviral protease inhibitor combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Retroviral protease inhibitor combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral protease inhibitor combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150506